Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
COCP 
Cocrystal Pharma Inc (COCP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: COCP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8
1 Year Target Price $8
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.84% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.11M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 2 | Beta 2.07 | 52 Weeks Range 1.12 - 3.26 | Updated Date 08/29/2025 |
52 Weeks Range 1.12 - 3.26 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.24 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.37 | Actual -0.2 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.87% | Return on Equity (TTM) -110.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12998419 | Price to Sales(TTM) 92.45 |
Enterprise Value 12998419 | Price to Sales(TTM) 92.45 | ||
Enterprise Value to Revenue 17.89 | Enterprise Value to EBITDA 0.66 | Shares Outstanding 10258900 | Shares Floating 6639846 |
Shares Outstanding 10258900 | Shares Floating 6639846 | ||
Percent Insiders 36.05 | Percent Institutions 6.69 |
Upturn AI SWOT
Cocrystal Pharma Inc
Company Overview
History and Background
Cocrystal Pharma, Inc. was founded in 2007. It focuses on discovering and developing novel antiviral therapeutics. The company's strategy involves using its cocrystal technology platform to create new and improved versions of existing antiviral drugs and to discover new antiviral compounds.
Core Business Areas
- Antiviral Drug Development: Focuses on the development of antiviral drugs to treat viral infections such as influenza, norovirus, and coronaviruses.
- Cocrystal Technology: Utilizes proprietary cocrystal technology to create new and improved versions of existing antiviral drugs. This involves modifying the physical and chemical properties of drugs to enhance their efficacy, bioavailability, and safety.
Leadership and Structure
The company is led by a team of scientists and business professionals with experience in drug discovery and development. Organizational structure involves research and development, clinical operations, and administrative functions.
Top Products and Market Share
Key Offerings
- CC-42344: A broad-spectrum oral antiviral drug in preclinical development targeting replication of influenza A strains, including seasonal and pandemic strains, as well as highly pathogenic avian strains. No current market share data is available as it's still in preclinical development. Competitors include Roche (Tamiflu), and other companies developing novel influenza therapies.
- CC-31244: A broad-spectrum oral antiviral drug in preclinical development for coronaviruses, including SARS-CoV-2 (COVID-19). No current market share data as in preclinical development. Competitors include Pfizer (Paxlovid), Merck (Molnupiravir) and other companies involved in coronavirus drug development.
Market Dynamics
Industry Overview
The antiviral drug market is driven by the ongoing threat of viral infections, including influenza, coronaviruses, and other emerging viruses. The market is characterized by intense competition, with pharmaceutical companies constantly seeking to develop new and improved antiviral therapies.
Positioning
Cocrystal Pharma aims to differentiate itself through its cocrystal technology, which offers the potential to create drugs with improved properties compared to existing therapies. Their competitive advantage lies in their ability to develop novel antiviral drugs and improved versions of existing drugs using this technology.
Total Addressable Market (TAM)
The global antiviral drug market is expected to reach hundreds of billions by the next decade. Cocrystal Pharma is positioned to potentially capture a portion of this market through successful development and commercialization of its antiviral drug candidates. However, it is a small, preclinical company with a high risk profile.
Upturn SWOT Analysis
Strengths
- Proprietary cocrystal technology platform
- Potential for improved drug efficacy and bioavailability
- Focus on developing drugs for unmet medical needs
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Preclinical stage of drug development
Opportunities
- Partnerships with larger pharmaceutical companies
- Government funding for antiviral drug development
- Emergence of new viral threats
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Failure of clinical trials
Competitors and Market Share
Key Competitors
- PFE
- MRK
- RO.SW
Competitive Landscape
Cocrystal Pharma is a small player in a highly competitive market dominated by large pharmaceutical companies. Its advantages lie in its cocrystal technology but has the disadvantage of itu2019s size and limited funding compared to competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in the advancement of its drug candidates through preclinical development. There has been no real revenue growth.
Future Projections: Future growth is contingent on the successful completion of clinical trials and subsequent commercialization of its drug candidates. Analyst estimates are highly speculative given the stage of development.
Recent Initiatives: Focus on advancing CC-42344 and CC-31244 through preclinical and clinical development.
Summary
Cocrystal Pharma is a high-risk, high-reward preclinical pharmaceutical company. Its cocrystal technology offers potential for novel antiviral drug development, but it faces significant challenges due to its limited resources and dependence on successful clinical trials. Positive clinical trial results would have significant impact on the value of the stock. It should proceed with securing funding to advance its drug pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual risk tolerance and after consulting with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cocrystal Pharma Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 2011-05-19 | Co-Founder, Co-CEO & President Dr. Sam Lee Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://www.cocrystalpharma.com |
Full time employees 11 | Website https://www.cocrystalpharma.com | ||
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.